← Leaderboards
Mary Albrecht
Beth Israel Deaconess Medical Center
$387,832
Attributed
$387,832
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$387,832 · 7
By mechanism
M01$387,832 · 7
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Bruce J Dezube$965,277
- Scott Hammer$387,832
- Rebecca Marie Zash$3,541,756
- Maria Serena Longhi$3,119,696
- Clyde S Crumpacker$2,475,664
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHiv InfectionsAids TherapyClinical ResearchHuman Therapy EvaluationCombination ChemotherapyAntiaids AgentZidovudineLamivudineProtease InhibitorIndinavirVirus ReplicationStavudineReverse Transcriptase InhibitorsDrug Screening /EvaluationHydroxyureaCd4 MoleculeClinical Trial Phase IDrug Resistance2'3'DideoxyinosineNevirapineRitonavirSaquinavirVirus Rna
Grant awards (32)
ACTG 5025--HYDROXYUREA IN POTENT ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
ACTG 373: APRENAVIR + 3TC + ZDV;INDINAVIR + NEVIRAPINE + 3TC + STAVU$0
M01 · FY2002 · RR
ACTG 343: THREE MAINTENANCE REGIMENS FOR HIV INFECTED SUBJECTS$0
M01 · FY2002 · RR
ACTG 359: SAQUINAVIR IN COMBINATION W/ RITONAVIR OR NELFINAVIR$0
M01 · FY2002 · RR
ACTG 384: PROTEASE INHIBITOR &NON NUCLEOSIDE REVERSE TRANSCRIPTASE I$0
M01 · FY2002 · RR
ACTG 388: EFZ OR NFV IN COMBINATION W/ FDC 3TC/ZDV &IDV$0
M01 · FY2002 · RR
ACTG 5025--HYDROXYUREA IN POTENT ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
ACTG 343: THREE MAINTENANCE REGIMENS FOR HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
ACTG 359: SAQUINAVIR IN COMBINATION W/ RITONAVIR OR NELFINAVIR$0
M01 · FY2001 · RR
ACTG 384: PROTEASE INHIBITOR &NON NUCLEOSIDE REVERSE TRANSCRIPTASE I$0
M01 · FY2001 · RR
ACTG 388: EFZ OR NFV IN COMBINATION W/ FDC 3TC/ZDV &IDV$0
M01 · FY2001 · RR
ACTG 373: APRENAVIR + 3TC + ZDV;INDINAVIR + NEVIRAPINE + 3TC + STAVU$0
M01 · FY2001 · RR
ACTG 347: PHASE II STUDY OF 141W94 &VS 478 MONOTHERAPY VS PLUS ZDV &$193,916
M01 · FY2000 · RR
ACTG 347: PHASE II STUDY OF 141W94 &VS 478 MONOTHERAPY VS PLUS ZDV &$193,916
M01 · FY2000 · RR
ACTG 343: THREE MAINTENANCE REGIMENS FOR HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 5025--HYDROXYUREA IN POTENT ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
ACTG 5025--HYDROXYUREA IN POTENT ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
ACTG 5025--HYDROXYUREA IN POTENT ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
ACTG 373: APRENAVIR + 3TC + ZDV;INDINAVIR + NEVIRAPINE + 3TC + STAVU$0
M01 · FY2000 · RR
ACTG 343: THREE MAINTENANCE REGIMENS FOR HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 343: THREE MAINTENANCE REGIMENS FOR HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 359: SAQUINAVIR IN COMBINATION W/ RITONAVIR OR NELFINAVIR$0
M01 · FY2000 · RR
ACTG 359: SAQUINAVIR IN COMBINATION W/ RITONAVIR OR NELFINAVIR$0
M01 · FY2000 · RR
ACTG 359: SAQUINAVIR IN COMBINATION W/ RITONAVIR OR NELFINAVIR$0
M01 · FY2000 · RR
ACTG 384: PROTEASE INHIBITOR &NON NUCLEOSIDE REVERSE TRANSCRIPTASE I$0
M01 · FY2000 · RR
ACTG 384: PROTEASE INHIBITOR &NON NUCLEOSIDE REVERSE TRANSCRIPTASE I$0
M01 · FY2000 · RR
ACTG 384: PROTEASE INHIBITOR &NON NUCLEOSIDE REVERSE TRANSCRIPTASE I$0
M01 · FY2000 · RR
ACTG 388: EFZ OR NFV IN COMBINATION W/ FDC 3TC/ZDV &IDV$0
M01 · FY2000 · RR
ACTG 388: EFZ OR NFV IN COMBINATION W/ FDC 3TC/ZDV &IDV$0
M01 · FY2000 · RR
ACTG 388: EFZ OR NFV IN COMBINATION W/ FDC 3TC/ZDV &IDV$0
M01 · FY2000 · RR
ACTG 373: APRENAVIR + 3TC + ZDV;INDINAVIR + NEVIRAPINE + 3TC + STAVU$0
M01 · FY2000 · RR
ACTG 373: APRENAVIR + 3TC + ZDV;INDINAVIR + NEVIRAPINE + 3TC + STAVU$0
M01 · FY2000 · RR